期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 228, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.114030
关键词
COVID-19; Structure-activity relationships; SARS-CoV-2 3CL(pro); 9,10-Dihydrophenanthrenes
资金
- National Natural Science Foundation of China [81903423, 21871184, 22071155, 81922070, 81973286]
- Shanghai Sailing Program [19YF1449300]
- Shanghai Municipal Education Commission [2019-01-07-00-10-E00072]
- Science and Technology Commission of Shanghai Municipality [18401933500, 20400750300]
- Shanghai Science and Technology Innovation Action Plan biomedical technology support special project [21S21900600]
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine [ZYYCXTD-D-202004]
In this study, 9,10-dihydrophenanthrene derivatives were discovered as non-peptidomimetic and non-covalent inhibitors of SARS-CoV-2 3CL(pro). Among the tested compounds, C1 and C2 showed the most potent inhibition activity. Further experiments revealed that these compounds dose-dependently inhibit SARS-CoV-2 3CL(pro) and exhibit good metabolic stability.
The epidemic coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread worldwide and efficacious therapeutics are urgently needed. 3-Chymotrypsin-like cysteine protease (3CL(pro)) is an indispensable protein in viral replication and represents an attractive drug target for fighting COVID-19. Herein, we report the discovery of 9,10-dihydrophenanthrene derivatives as non-peptidomimetic and non-covalent inhibitors of the SARS-CoV-2 3CL(pro). The structure-activity relationships of 9,10-dihydrophenanthrenes as SARS-CoV-2 3CL(pro) inhibitors have carefully been investigated and discussed in this study. Among all tested 9,10-dihydrophenanthrene derivatives, C1 and C2 display the most potent SARS-CoV-2 3CL(pro) inhibition activity, with IC50 values of 1.55 +/- 0.21 mu M and 1.81 +/- 0.17 mu M, respectively. Further enzyme kinetics assays show that these two compounds dose-dependently inhibit SARS-CoV-2 3CL(pro) via a mixed-inhibition manner. Molecular docking simulations reveal the binding modes of C1 in the dimer interface and substrate-binding pocket of the target. In addition, C1 shows outstanding metabolic stability in the gastrointestinal tract, human plasma, and human liver microsome, suggesting that this agent has the potential to be developed as an orally administrated SARS-CoV-2 3CL(pro) inhibitor. (c) 2021 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据